Omeprazole Noridem (Omeprazole Sodium)

Omeprazole, the active ingredient in Omeprazole Noridem, is a proton pump inhibitor presented as a intravenous solution for IV use. It reduces gastric acid secretion and is used in the management of acid‑related gastrointestinal conditions in hospitalised patients. GNH USA supplies Omeprazole Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Omeprazole Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omeprazole Noridem is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related conditions: - Peptic ulcer disease: promotes healing of gastric and duodenal ulcers. - Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and esophageal irritation. - Stress‑related mucosal damage: prevents ulcer formation in critically ill patients. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to enhance ulcer healing. - NSA‑ID prophylaxis: reduces risk of ulcer development in patients receiving non‑steroidal anti‑inflammatory drugs.

Omeprazole Noridem may cause a range of adverse reactions. The profile includes both frequent and rare events.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas formation. - Constipation: infrequent bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Hypomagnesemia: low serum magnesium levels. - Acute interstitial nephritis: kidney inflammation. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatic dysfunction: elevated liver enzymes. - Anaphylaxis: immediate hypersensitivity reaction.

When using Omeprazole Noridem, several safety considerations should be observed: - Renal impairment: adjust use in patients with severe kidney disease. - Hepatic impairment: monitor liver function in patients with liver disease. - Long‑term therapy: assess need for continued treatment to avoid nutrient deficiencies. - Drug interactions: review concomitant medications for potential PK/PD effects. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ometom  

---

---  

   t  

g  t

"""